Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Net Income (2021 - 2025)

Historic Net Income for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$52.8 million.

  • Prime Medicine's Net Income fell 59.79% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 896.7%. This contributed to the annual value of -$195.9 million for FY2024, which is 113.61% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Net Income is -$52.8 million, which was down 59.79% from -$52.6 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Net Income peaked at -$16.4 million during Q3 2021, and registered a low of -$65.6 million during Q4 2023.
  • Its 5-year average for Net Income is -$44.3 million, with a median of -$45.8 million in 2024.
  • The largest annual percentage gain for Prime Medicine's Net Income in the last 5 years was 3754.39% (2022), contrasted with its biggest fall of 7883.26% (2022).
  • Prime Medicine's Net Income (Quarter) stood at -$62.9 million in 2021, then soared by 37.54% to -$39.3 million in 2022, then crashed by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then fell by 24.97% to -$52.8 million in 2025.
  • Its last three reported values are -$52.8 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.